Floatz logo

Acthar Gel

Multiple Sclerosis, Relapsing-Remitting

Mallinckrodt ARD LLCPhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Multiple Sclerosis, Relapsing-Remitting cohort.

Asset / SponsorPhaseRating
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Universitätsklinikum Hamburg-Eppendorf
Phase 4BBB

View all 50 →

Same molecule, other indications

Acthar Gel is also rated in:

Dry EyeDormant
B
Indicative ·
60 / 100
View asset →
Neurotrophic KeratitisDormant
B
Indicative ·
60 / 100
View asset →
Autoimmune DiseasesDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →